


L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:964998 CAPLUS Full-text  
 DN 141:410970  
 TI Preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions  
 IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V., III; Marugan Sanchez, Juan Jose; Gushue, Joan; Leonard, Kristi  
 PA 3-Dimensional Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 166 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096134	A2	20041111	WO 2004-US12240	20040421
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-465265P	P	20030425		
OS	MARPAT 141:410970				
GI					



AB The title compds. [I; R = halo, alkyl, CN, cycloalkyl, etc.; n = 0-2; X X = a bivalent radical such as alkanediyl, etc.; R3 = CO2R0, CO2M (wherein R0 = H, alkyl, cycloalkyl; M = cation); R5 = cycloalkyl, aryl, heteroaryl, etc.; R6 = cycloalkyl, aryl, heteroaryl, etc.; R7 = H, alkyl, cycloalkyl, (cycloalkyl)alkyl; R8 = H, alkyl], useful as inhibitors of HDM2-p53 interactions for treating cancer, inflammatory condition or autoimmune disease, were prepared and formulated. E.g., a multi-step synthesis of II, which showed IC50 of 0.1-1.0  $\mu$ M against binding of p53 to MDM2, was given.  
 IT 787632-90-0P 787632-91-1P 787632-92-2P  
 787632-93-3P 787632-94-4P 787632-95-5P  
 787632-96-6P 787632-97-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)  
 RN 787632-90-0 CAPLUS  
 CN 5H-1,4-Benzodiazepin-5-one, 2-amino-3-(4-chlorophenyl)-4-[(1R)-1-(4-

chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-91-1 CAPLUS

CN Acetamide, 2-[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-92-2 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(2-hydroxyethyl)amino]-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-93-3 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(3-hydroxypropyl)amino]-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-94-4 CAPLUS

CN Acetamide, N-[2-[[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]ethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787632-95-5 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-2-(methylamino)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-96-6 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 2-[(2-aminoethyl)amino]-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-97-7 CAPLUS


CN Propanamide, 3-[[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:934324 CAPLUS Full-text  
 DN 141:395589  
 TI Preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease.  
 IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V.; Marugan, Sanchez Juan Jose; Gushue, Joan; Leonard, Kristi  
 PA USA  
 SO U.S. Pat. Appl. Publ., 58 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2004220179	A1	20041104	US 2004-829040	20040421
	US 2005227932	A1	20051013	US 2005-72391	20050304
PRAI	US 2003-465264P	P	20030425		
	US 2002-292876	A2	20021113		
	US 2004-829040	A1	20040421		
OS	MARPAT 141:395589				
GI					




AB Title compds. e.g. [I; Ra = halo, alkyl, alkenyl, alkynyl, cyano, cycloalkyl, OH, alkoxy, CO<sub>2</sub>H, alkoxy carbonyl, acyl, carbamoyl, (alkyl)aminocarbonyl, alkylthio, amino, NO<sub>2</sub>; X = alkylene, cycloalkylene, (substituted) arylene, heteroarylene, arylalkylene, heteroarylalkylene; R<sub>3</sub> = CO<sub>2</sub>Rd, CO<sub>2</sub>M; Rd = H, alkyl; (substituted) cycloalkyl; M = cation; R<sub>5</sub>, R<sub>6</sub> = (substituted) cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, (unsatd.) heterocyclyl; R<sub>7</sub> = H, alkyl, cycloalkyl, cycloalkylalkyl; R<sub>8</sub> = H, alkyl; n = 0-2], were prepared Thus, 4-[(R)-1-(2-amino-4-chlorophenyl)ethyl]-(3S)-3-(4-chlorophenyl)-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-1,4-benzodiazepine-2,5-dione inhibited MDM2 binding to a p53 peptide analog with IC<sub>50</sub> = 0.1-1.0 μM.

IT 787632-90-0P 787632-91-1P 787632-92-2P  
 787632-93-3P 787632-94-4P 787632-95-5P  
 787632-96-6P 787632-97-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)

RN 787632-90-0 CAPLUS  
 CN 5H-1,4-Benzodiazepin-5-one, 2-amino-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-91-1 CAPLUS

CN Acetamide, 2-[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-92-2 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(2-hydroxyethyl)amino]-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-93-3 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(3-hydroxypropyl)amino]-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-94-4 CAPLUS

CN Acetamide, N-[2-[[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-95-5 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-2-(methylamino)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-96-6 CAPLUS

CN 5H-1,4-Benzodiazepin-5-one, 2-[(2-aminoethyl)amino]-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-97-7 CAPLUS


CN Propanamide, 3-[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





=> d l2; d his; log y  
 L2 HAS NO ANSWERS  
 L1 STR



G1 Cb,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.  
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 16:26:06 ON 30 NOV 2005)

FILE 'REGISTRY' ENTERED AT 16:26:14 ON 30 NOV 2005  
 L1 STRUCTURE UPLOADED  
 L2 QUE L1

FILE 'STNGUIDE' ENTERED AT 16:27:21 ON 30 NOV 2005

FILE 'REGISTRY' ENTERED AT 16:28:46 ON 30 NOV 2005  
 L3 0 S L2  
 L4 8 S L2 FUL

FILE 'CAPLUS' ENTERED AT 16:29:11 ON 30 NOV 2005  
 L5 2 S L4

FILE 'BEILSTEIN' ENTERED AT 16:29:38 ON 30 NOV 2005  
 L6 0 S L2  
 L7 0 S L2 FUL

FILE 'MARPAT' ENTERED AT 16:30:01 ON 30 NOV 2005  
 L8 0 S L2  
 L9 2 S L2 FUL  
 L10 0 S L9 NOT L5



COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	113.53	286.44
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.46

STN INTERNATIONAL LOGOFF AT 16:30:32 ON 30 NOV 2005

1-26 ~~126~~

L5 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:964998 CAPLUS Full-text  
 DN 141:410970  
 TI Preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions  
 IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V., III; Marugan Sanchez, Juan Jose; Gushue, Joan; Leonard, Kristi  
 PA 3-Dimensional Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 166 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096134	A2	20041111	WO 2004-US12240	20040421
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-465265P	P	20030425		
OS	MARPAT 141:410970				
GI					



AB The title compds. [I; R = halo, alkyl, CN, cycloalkyl, etc.; n = 0-2; X X = a bivalent radical such as alkanediyl, etc.; R3 = CO2R0, CO2M (wherein R0 = H, alkyl, cycloalkyl; M = cation); R5 = cycloalkyl, aryl, heteroaryl, etc.; R6 = cycloalkyl, aryl, heteroaryl, etc.; R7 = H, alkyl, cycloalkyl, (cycloalkyl)alkyl; R8 = H, alkyl], useful as inhibitors of HDM2-p53 interactions for treating cancer, inflammatory condition or autoimmune disease, were prepared and formulated. E.g., a multi-step synthesis of II, which showed IC50 of 0.1-1.0  $\mu$ M against binding of p53 to MDM2, was given.

IT **787632-98-8P 787632-99-9P**


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)

RN 787632-98-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-

chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methoxycarbonyl)-2,5-dioxo-,  
1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-99-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-carboxy-3-(4-chlorophenyl)-4-  
[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-,  
 $\alpha$ -(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 528849-68-5P 787632-60-4P 787632-61-5P  
787632-62-6P 787632-64-8P 787632-65-9P  
787632-66-0P 787632-67-1P 787632-68-2P  
787632-69-3P 787632-70-6P 787632-71-7P  
787632-72-8P 787632-73-9P 787632-74-0P  
787632-75-1P 787632-76-2P 787632-77-3P  
787632-78-4P 787632-79-5P 787632-80-8P  
787632-81-9P 787632-82-0P 787632-83-1P  
787632-84-2P 787632-85-3P 787632-86-4P  
787632-87-5P 787632-88-6P 787632-89-7P  
787633-00-5P 787633-01-6P 787633-02-7P  
787633-03-8P 787633-04-9P 787633-05-0P  
787633-06-1P 787633-07-2P 787633-08-3P  
787633-09-4P 787633-10-7P 787633-11-8P  
787633-15-2P 787633-16-3P 787633-17-4P  
787633-20-9P 787633-21-0P 787633-23-2P  
787633-24-3P 787633-25-4P 787633-26-5P  
787633-27-6P 787633-28-7P 787633-29-8P  
787633-30-1P 787633-33-4P 787633-34-5P  
787633-35-6P 787633-36-7P 787633-37-8P  
787633-38-9P 787633-40-3P 787633-43-6P  
787633-44-7P 787633-45-8P 787633-48-1P  
787633-49-2P 787633-50-5P 787633-51-6P  
787633-52-7P 787633-53-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53  
interactions)


RN 528849-68-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI)  
(CA INDEX NAME)



RN 787632-60-4 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA  
INDEX NAME)



RN 787632-61-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 787632-62-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 787632-64-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-65-9 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-66-0 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-67-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-68-2 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-69-3 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethyl)phenyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-70-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethoxy)phenyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-71-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-hexanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-72-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-heptanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-73-9 CAPLUS

CN Benzoic acid, 4-[[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787632-74-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-butanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 787632-75-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-propanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-76-2 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-77-3 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 8-chloro-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787632-78-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)cyclopropylmethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI)  
(CA INDEX NAME)




RN 787632-79-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(3,4-dichlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 787632-80-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(3-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 787632-81-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-3-nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-(9CI) (CA INDEX NAME)




RN 787632-82-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-4-[1-(4-methyl-1-naphthalenyl)ethyl]-2,5-dioxo-(9CI) (CA INDEX NAME)




RN 787632-83-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-(9CI) (CA INDEX NAME)



RN 787632-84-2 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[2-(4-chlorophenyl)-1-methylethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI)  
(CA INDEX NAME)



RN 787632-85-3 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-bromophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-86-4 CAPLUS


CN 1H-1,4-Benzodiazepine-1-acetic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 787632-87-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-3-nitrophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787632-88-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787632-89-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-amino-4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787633-00-5 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-(aminocarbonyl)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-01-6 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (9CI) (CA INDEX NAME)



RN 787633-02-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 787633-03-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-04-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-05-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 787633-06-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 787633-07-2 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-08-3 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3R)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 787633-09-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-[(trifluoromethyl)thio]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-10-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-11-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-15-2 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(2-methylphenyl)-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 787633-16-3 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 787633-17-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(2-amino-4-chlorophenyl)methyl]-7-bromo-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 787633-20-9 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-fluorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-21-0 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-hydroxyphenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 787633-23-2 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-1-[4-(dimethylamino)butyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)




RN 787633-24-3 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)



RN 787633-25-4 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[4-(4-methyl-1-piperazinyl)butyl]- (9CI) (CA INDEX NAME)



RN 787633-26-5 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-

chlorophenyl)-1-[3-(dimethylamino)propyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)




RN 787633-27-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787633-28-7 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-hydroxyphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-29-8 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-30-1 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]-(9CI) (CA INDEX NAME)




RN 787633-33-4 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 787633-34-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 787633-35-6 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(4-chloro-2-nitrophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-36-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-(1-propynyl)-, sodium salt, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 787633-37-8 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-38-9 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-40-3 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-methyl- (9CI) (CA INDEX NAME)



RN 787633-43-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 787633-44-7 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 787633-45-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-6-chloro-3-pyridinyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 787633-48-1 CAPLUS

CN Piperazine, 1-[[[(3S)-4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-

chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 787633-49-2 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-50-5 CAPLUS

CN Morpholine, 4-[[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-51-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-52-7 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-53-8 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 787633-93-6 787633-94-7 787633-98-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)  
 RN 787633-93-6 CAPLUS  
 CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-94-7 CAPLUS  
 CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-98-1 CAPLUS  
 CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 787633-63-0P 787633-64-1P 787633-71-0P  
787633-83-4P 787633-84-5P 787633-85-6P  
787633-95-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53  
interactions)

RN 787633-63-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-  
chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-,  
1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-64-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-  
chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-71-0 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-83-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-2-nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-84-5 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-85-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-bromo-4-[(4-chloro-2-nitrophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-,


1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-95-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 791613-68-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)

RN 791613-68-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



App's

L5 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:934324 CAPLUS Full-text  
 DN 141:395589  
 TI Preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions  
 for treatment of cancer and autoimmune disease.  
 IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell  
 David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V.; Marugan,  
 Sanchez Juan Jose; Gushue, Joan; Leonard, Kristi  
 PA USA  
 SO U.S. Pat. Appl. Publ., 58 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004220179	A1	20041104	US 2004-829040	20040421
	US 2005227932	A1	20051013	US 2005-72391	20050304
PRAI	US 2003-465264P	P	20030425		
	US 2002-292876	A2	20021113		
	US 2004-829040	A1	20040421		
OS	MARPAT 141:395589				
GI					



AB Title compds. e.g. [I; Ra = halo, alkyl, alkenyl, alkynyl, cyano, cycloalkyl, OH, alkoxy, CO<sub>2</sub>H, alkoxycarbonyl, acyl, carbamoyl, (alkyl)aminocarbonyl, alkylthio, amino, NO<sub>2</sub>; X = alkylene, cycloalkylene, (substituted) arylene, heteroarylene, arylalkylene, heteroarylalkylene; R<sub>3</sub> = CO<sub>2</sub>Rd, CO<sub>2</sub>M; Rd = H, alkyl, (substituted) cycloalkyl; M = cation; R<sub>5</sub>, R<sub>6</sub> = (substituted) cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, (unsatd.) heterocyclyl; R<sub>7</sub> = H, alkyl, cycloalkyl, cycloalkylalkyl; R<sub>8</sub> = H, alkyl; n = 0-2], were prepared Thus, 4-[(R)-1-(2-amino-4-chlorophenyl)ethyl]-(3S)-3-(4-chlorophenyl)-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-1,4-benzodiazepine-2,5-dione inhibited MDM2 binding to a p53 peptide analog with IC<sub>50</sub> = 0.1-1.0 μM.

IT **787632-60-4P**, 4-[1-(2-Amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-7-iodo-1-[2-(4-morpholino)ethyl]-1,4-benzodiazepine-2,5-dione **787632-61-5P 787632-62-6P 787632-64-8P 787632-65-9P 787632-66-0P 787632-67-1P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)

RN 787632-60-4 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)






RN 787632-61-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 787632-62-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 787632-64-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-65-9 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-66-0 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-67-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)-(9CI) (CA


Absolute stereochemistry.



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 528849-68-5 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI)  
(CA INDEX NAME)



RN 787632-68-2 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787632-69-3 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-70-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethoxy)phenyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-71-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-hexanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-72-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-heptanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-73-9 CAPLUS

CN Benzoic acid, 4-[[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787632-74-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-butanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 787632-75-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-propanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-76-2 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787632-77-3 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 8-chloro-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)-


(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787632-78-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)cyclopropylmethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI)  
(CA INDEX NAME)




RN 787632-79-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(3,4-dichlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 787632-80-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(3-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 787632-81-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-3-nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-(9CI) (CA INDEX NAME)



RN 787632-82-0 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-4-[1-(4-methyl-1-naphthalenyl)ethyl]-2,5-dioxo-(9CI) (CA INDEX NAME)



RN 787632-83-1 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-(9CI) (CA INDEX NAME)





RN 787632-84-2 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[2-(4-chlorophenyl)-1-methylethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI)  
(CA INDEX NAME)



RN 787632-85-3 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-bromophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-86-4 CAPLUS


CN 1H-1,4-Benzodiazepine-1-acetic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 787632-87-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-3-nitrophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787632-88-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787632-89-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-amino-4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787632-98-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methoxycarbonyl)-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787632-99-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-carboxy-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-,  $\alpha$ -(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-00-5 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-(aminocarbonyl)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-01-6 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787633-02-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 787633-03-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-04-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787633-05-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 787633-06-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 787633-07-2 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-08-3 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-09-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-[(trifluoromethyl)thio]-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-10-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-11-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-15-2 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(2-methylphenyl)-2,5-dioxo-,

sodium salt, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 787633-16-3 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 787633-17-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(2-amino-4-chlorophenyl)methyl]-7-bromo-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 787633-20-9 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-



fluorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-21-0 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-hydroxyphenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 787633-23-2 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-1-[4-(dimethylamino)butyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)




RN 787633-24-3 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)




RN 787633-25-4 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[(4-(4-methyl-1-piperazinyl)butyl)-(9CI) (CA INDEX NAME)




RN 787633-26-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-1-[3-(dimethylamino)propyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)




RN 787633-27-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787633-28-7 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-hydroxyphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-29-8 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-30-1 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 787633-33-4 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(phenylethyl)- (9CI) (CA INDEX NAME)




RN 787633-34-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 787633-35-6 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(4-chloro-2-nitrophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-36-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-(1-propynyl)-, sodium salt, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 787633-37-8 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-38-9 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-40-3 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-methyl- (9CI) (CA INDEX NAME)



RN 787633-43-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 787633-44-7 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)




CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-6-chloro-3-pyridinyl)methyl]-  
3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)



CN Piperazine, 1-[[[(3S)-4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)


● HCl

RN 787633-49-2 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-50-5 CAPLUS  
 CN Morpholine, 4-[[ (3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-51-6 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 787633-52-7 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-53-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 787633-93-6 787633-94-7 787633-95-8  
787633-98-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)

RN 787633-93-6 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-94-7 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-95-8 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 787633-98-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**



IT 787633-63-0P 787633-64-1P 787633-71-0P  
 787633-83-4P 787633-84-5P 787633-85-6P  
 787634-02-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions  
 for treatment of cancer and autoimmune disease)

RN 787633-63-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-  
 chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-,  
 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-64-1 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-  
 chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787633-71-0 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-  
 [(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-,  
 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787633-83-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-2-  
 nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 787633-84-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-  
 chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-85-6 CAPLUS


CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-bromo-4-[(4-chloro-2-  
 nitrophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787634-02-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-(aminocarbonyl)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:913286 CAPLUS Full-text

DN 140:776

TI Method using benzodiazepine compounds for cytoprotection through MDM2 and HDM2 inhibition

IN Koblish, Holly K.; Manthey, Carl L.; Molloy, Christopher J.; Lu, Tianbao; Parks, Daniel J.; Lafrance, Luis V., III; Milkiewicz, Karen L.; Carver, Ted; Grasberger, Bruce L.

PA 3-Dimensional Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095625	A2	20031120	WO 2003-US14923	20030513
	WO 2003095625	A3	20040715		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2002-379617P P 20020513

OS MARPAT 140:776


AB The invention provides a method for protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class of 1,4-benzodiazepines which act as inhibitors of MDM2-p53 interactions. The method of the invention can be employed as an adjunct to chemotherapy or radiation therapy. In addition, the methods of the invention can be employed to treat a disease or condition that involves excessive cell death.

IT 528848-14-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(benzodiazepine compds. for cytoprotection through MDM2 and HDM2 inhibition)



RN 528848-14-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[(4-methylphenyl)methyl]-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:396722 CAPLUS Full-text  
 DN 138:401764  
 TI Preparation of substituted 1,4-benzodiazepinediones as MDM2 oncoprotein inhibitors for the treatment of cancer  
 IN Lu, Tianbao; Lafrance, Louis V., III; Parks, Daniel J.; Milkiewicz, Karen L.; Calvo, Raul R.; Cummings, Maxwell David; Kim, Alexander J.; Grasberger, Bruce L.; Carver, Theodore E., Jr.  
 PA 3-Dimensional Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 139 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003041715	A1	20030522	WO 2002-US36208	20021113
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2466055	AA	20030522	CA 2002-2466055	20021113
	US 2003109518	A1	20030612	US 2002-292876	20021113
	EP 1443937	A1	20040811	EP 2002-778828	20021113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014048	A	20041013	BR 2002-14048	20021113
	JP 2005509005	T2	20050407	JP 2003-543602	20021113
	ZA 2004003082	A	20050422	ZA 2004-3082	20040422
	NO 2004002146	A	20040811	NO 2004-2146	20040525
PRAI	US 2001-331235P	P	20011113		
	WO 2002-US36208	W	20021113		
OS	MARPAT 138:401764				
GI					



AB Title compds. I [wherein X and Y = independently CO, CH<sub>2</sub>, or CS; R<sub>1</sub>-R<sub>4</sub> = independently H, halo, (cyclo)alkyl, alkenyl, alkynyl, alkoxy(carbonyl), CN, NH<sub>2</sub>, alkanoylamino, NO<sub>2</sub>, OH, CO<sub>2</sub>H, and (un)substituted (hetero)aryl, (hetero)aralkyl, or (hetero)aryloxy; or R<sub>1</sub>R<sub>2</sub>, R<sub>2</sub>R<sub>3</sub>, or R<sub>3</sub>R<sub>4</sub> = (CH<sub>2</sub>)<sub>u</sub>, CH=CHCH=CH, or CH<sub>2</sub>CH=CHCH<sub>2</sub>; u = 3-6; R<sub>5</sub> = H, (cyclo)alkyl, carboxyalkyl, alkoxy carbonyl(alkyl), (alkyl)aminocarbonyl(alkyl), or (un)substituted (hetero)aryl or (hetero)aralkyl; R<sub>6</sub> and R<sub>9</sub> = independently (un)substituted cycloalkyl(alkyl), (hetero)aryl, (hetero)aralkyl, or heterocyclyl; R<sub>7</sub> and R<sub>8</sub> = independently H or alkyl; R<sub>10</sub> = (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>b</sub>, (CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>M, (CH<sub>2</sub>)<sub>i</sub>OH, or (CH<sub>2</sub>)<sub>j</sub>CONR<sub>c</sub>R<sub>d</sub>; R<sub>b</sub> = H, alkyl, or (un)substituted cycloalkyl or heterocyclyl; M



= a cation; Rc and Rd = independently H or (un)substituted (cyclo)alkyl, (hetero)alkyl, (hetero)aralkyl, or heterocyclyl; n = 0-8; m = 0-8; i = 1-8; j = 0-8; and solvates, hydrates, and pharmaceutically acceptable salts thereof] were prepared as inhibitors of HDM2-p53 interactions. Examples include general synthetic procedures and phys. data for 216 invention compds., as well as exptl. details and results from a fluorescent peptide assay. For instance, the benzodiazepinedione II, which was prepared starting from an anthranilic acid derivative, inhibited the binding of a p53 peptide analog to MDM2 residues 17-125 with an IC50 value of 1.7  $\mu$ M. Thus, I are useful for the prevention or treatment of a variety of cancers, inflammatory conditions, and autoimmune diseases (no data).

IT 528848-05-7P, [1-Benzyl-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-06-8P, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-phenethyl-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-07-9P, [3-(4-Chlorophenyl)-7-iodo-1-isobutyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-08-0P, [3-(4-Chlorophenyl)-7-iodo-1-(3-methylbutyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-09-1P, [3-(4-Chlorophenyl)-1-cyclobutylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-10-4P, [3-(4-Chlorophenyl)-1-cyclopentylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-11-5P, [3-(4-Chlorophenyl)-1-cyclohexylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-12-6P, [3-(4-Chlorophenyl)-7-iodo-1-(2-methylbenzyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-13-7P, [3-(4-Chlorophenyl)-7-iodo-1-(3-methylbenzyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-14-8P, [3-(4-Chlorophenyl)-7-iodo-1-(4-methylbenzyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-15-9P, [3-(4-Chlorophenyl)-7-iodo-1-(naphthalen-2-yl)methyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-16-0P, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(pyridin-2-yl)methyl-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-17-1P, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(pyridin-3-yl)methyl-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-18-2P, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(pyridin-4-yl)methyl-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-21-7P, [3-(4-Chlorophenyl)-7-iodo-1-methyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528848-22-8P, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(3-phenylpropyl)-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid  
 528849-41-4P, 3-[4-[(Carboxy)(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-2,3,4,5-tetrahydrobenzo[e][1,4]diazepin-1-yl]propionic acid  
 528849-43-6P, [1-(2-tert-Butoxycarbonylaminoethyl)-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl](4-chlorophenyl)acetic acid  
 528849-45-8P, (4-Chlorophenyl)[3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1-[2-(pyridin-2-yl)ethyl]-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid  
 528849-46-9P, (4-Chlorophenyl)[3-(4-chlorophenyl)-7-iodo-1-(methylcarbamoylmethyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid  
 528849-49-2P, (4-Chlorophenyl)[3-(4-chlorophenyl)-7-iodo-1-methyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid  
 528849-51-6P, [1-Carboxymethyl-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl](4-chlorophenyl)acetic acid methyl ester  
 528849-53-8P, (4-Chlorophenyl)[3-(4-chlorophenyl)-1-(R)-2,3-dihydroxypropyl]-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid  
 528849-66-3P,

(4-Chlorophenyl) [3-(4-chlorophenyl)-1-((S)-2,3-dihydroxypropyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid


**528849-67-4P**, 5-[4-[(Carboxy)(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-2,3,4,5-tetrahydrobenzo[e][1,4]diazepin-1-yl]pentanoic acid **528849-68-5P**, 5-[3-(4-Chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-7-iodo-2,5-dioxo-2,3,4,5-tetrahydrobenzo[e][1,4]diazepin-1-yl]pentanoic acid **528849-69-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anticancer agent; preparation of benzodiazepinediones as p53 MDM2 binding inhibitors for treatment of cancer, inflammatory conditions, and autoimmune diseases)


RN 528848-05-7 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 528848-06-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 528848-07-9 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-(2-methylpropyl)-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)




RN 528848-08-0 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-(3-methylbutyl)-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)




RN 528848-09-1 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1-(cyclobutylmethyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)



RN 528848-10-4 CAPLUS


CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1-(cyclopentylmethyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)



RN 528848-11-5 CAPLUS


CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1-

(cyclohexylmethyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl-  
(9CI) (CA INDEX NAME)




RN 528848-12-6 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-  
7-iodo-1-[(2-methylphenyl)methyl]-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA  
INDEX NAME)




RN 528848-13-7 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-  
7-iodo-1-[(3-methylphenyl)methyl]-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA  
INDEX NAME)




RN 528848-14-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[(4-methylphenyl)methyl]-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)




RN 528848-15-9 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-(2-naphthalenylmethyl)-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)




RN 528848-16-0 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 528848-17-1 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 528848-18-2 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 528848-21-7 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-methyl-2,5-dioxo- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)




RN 528848-22-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- $\alpha$ -phenyl-1-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 528849-41-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-propanoic acid, 4-[carboxy(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 528849-43-6 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid,  $\alpha$ ,3-bis(4-chlorophenyl)-1-[2-[[ (1,1-dimethylethoxy) carbonyl] amino]ethyl]-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 528849-45-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid,  $\alpha$ ,3-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-1-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 528849-46-9 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid,  $\alpha$ ,3-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[2-(methylamino)-2-oxoethyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-49-2 CAPLUS


CN 4H-1,4-Benzodiazepine-4-acetic acid,  $\alpha$ ,3-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-51-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1,4(5H)-diacetic acid,  $\alpha$ 4,3-bis(4-chlorophenyl)-2,3-dihydro-7-iodo-2,5-dioxo-, 4-methyl ester (9CI) (CA INDEX NAME)






RN 528849-53-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid,  $\alpha$ ,3-bis(4-chlorophenyl)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528849-66-3 CAPLUS


CN 4H-1,4-Benzodiazepine-4-acetic acid,  $\alpha$ ,3-bis(4-chlorophenyl)-1-[(2S)-2,3-dihydroxypropyl]-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 528849-67-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[carboxy(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 528849-68-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI)  
(CA INDEX NAME)




RN 528849-69-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-(diethylamino)-2-oxoethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:320256 CAPLUS Full-text  
 DN 140:77117  
 TI Diastereoselective alkylation of a chiral 1,4-benzodiazepine-2,5-dione containing the  $\alpha$ -phenethyl group. Attempted asymmetric synthesis of  $\alpha,\beta$ -diaminopropionic acid  
 AU Becerril, Amayaly; Leon-Romo, Jose Luis; Avina, Judit; Castellanos, Elena; Juaristi, Eusebio  
 CS Departamento de Quimica, Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico, D.F., 07000, Mex.  
 SO ARKIVOC (Gainesville, FL, United States) (2002), (12), 4-14  
 CODEN: AGFUAR  
 URL: <http://www.arkat-usa.org/ark/journal/2002/Muchowski/JM-602F/602F.pdf>  
 PB Arkat USA Inc.  
 DT Journal; (online computer file)  
 LA English  
 OS CASREACT 140:77117  
 GI



AB Alkylation of chiral benzodiazepinedione (S)-I with LDA or LHMDS with N-(bromomethyl)-phthalimide (a protected derivative of bromomethylamine), via the lithium enolate of (S)-I in the presence of HMPA as cosolvent was accomplished in moderate yield and good diastereoselectivity. Hydrolysis of the resultant major diastereomeric product (S,R)-II with 57% HI afforded the desired  $\alpha,\beta$ -aminopropionic acid in good yield albeit in racemic form, probably due to  $\beta$ -elimination-addition of ammonia under these conditions.  
 IT **641630-70-8P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (base promoted diastereoselective alkylation of chiral N-methyl-N'-phenethylbenzodiazepinedione)  
 RN 641630-70-8 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3,4-dihydro-1-methyl-4-[(1S)-1-phenylethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 641630-71-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(base promoted diastereoselective alkylation of chiral  
N-methyl-N'-phenethylbenzodiazepinedione)

RN 641630-71-9 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3,4-dihydro-1-methyl-4-[(1S)-1-phenylethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:242698 CAPLUS Full-text  
 DN 138:385412  
 TI Solid-Phase Synthesis of 7-Acylamino-1,4-benzodiazepine-2,5-diones  
 AU Ettmayer, Peter; Chloupek, Stefan; Weigand, Klaus  
 CS Novartis Forschungsinstitut, Vienna, A-1235, Austria  
 SO Journal of Combinatorial Chemistry (2003), 5(3), 253-259  
 CODEN: JCCHFF; ISSN: 1520-4766  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 138:385412  
 AB A method for the synthesis of polymer-bound 7-acylamino-benzodiazepine-2,5-diones is described. The amino group of an  $\alpha$ -amino acid is linked to polystyrene or TentaGel resin via reductive amination of polymer-bound 4-alkoxy-2,6-dimethoxybenzaldehyde. Acylation with unprotected 5-nitroanthranilic acid is followed by base-catalyzed ring closure. Reduction of the nitro group yields enantiomerically pure 7-aminobenzodiazepin-2,5-dione attached via the N-4 atom to the resin. Acylation of the amino group on the aromatic ring with acid chlorides in N-methylpyrrolidone (no DMF, no base) followed by cleavage from the resin using TFA/Me<sub>2</sub>S/water (90:5:5) provides the acylated benzodiazepinones in 52-69% (PS resin) and 41-48% (TG resin) yield (based on the theor. loading) and >70% purity (HPLC, 210 nm). Using Fmoc-protected tyrosine fluoride in NMP gives the amino acid-coupled benzodiazepinones in 24% (PS resin) and 31% (TG resin) yield.  
 IT **528603-50-1DP**, polymer-supported **528603-52-3DP**, polymer-supported  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (solid-phase synthesis of 7-acylamino-1,4-benzodiazepine-2,5-diones)  
 RN 528603-50-1 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(cyclohexylmethyl)-3,4-dihydro-4-[(4-hydroxy-2,6-dimethoxyphenyl)methyl]-1-methyl-7-nitro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528603-52-3 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 7-amino-3-(cyclohexylmethyl)-3,4-dihydro-4-[(4-hydroxy-2,6-dimethoxyphenyl)methyl]-1-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10      THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:172564 CAPLUS Full-text

DN 136:355222

TI A New Resin-Bound Universal Isonitrile for the Ugi 4CC Reaction:  
Preparation and Applications to the Synthesis of 2,5-Diketopiperazines and  
1,4-Benzodiazepine-2,5-diones

AU Kennedy, April L.; Fryer, Andrew M.; Josey, John A.

CS Array BioPharma, Boulder, CO, 80301, USA

SO Organic Letters (2002), 4(7), 1167-1170

CODEN: ORLEF7; ISSN: 1523-7060

PB American Chemical Society

DT Journal

LA English

OS CASREACT 136:355222



AB The preparation and synthetic applications of a novel resin-bound isonitrile are described. The resin is an example of a novel convertible isonitrile that can be utilized in the Ugi multicomponent reaction. Base-activation of the resin-bound Ugi product results in cleavage via formation of a N-acyloxazolidone that is then trapped as a carboxylic acid ester. This resin and the methodol. described are suitable for synthesizing diversity libraries of 2,5-diketopiperazines and 1,4-benzodiazepine-2,5-diones.

IT 422309-10-2P 422309-12-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of 2,5-diketopiperazine and 1,4-benzodiazepine-2,5-dione  
libraries via Ugi four-component condensation with polymer-supported  
isocyanide)



RN 422309-10-2 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[2-(4-chlorophenyl)ethyl]-3-cyclohexyl-  
3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 422309-12-4 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3-cyclohexyl-3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:115088 CAPLUS Full-text  
 DN 134:178141  
 TI Preparation of oxoazacycloalkanes and analogs  
 IN Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrisette, Mathew M.; Ma, Liang; Cherrier, Marie-Pierre  
 PA Aventis Pharmaceuticals Products, Inc., USA  
 SO PCT Int. Appl., 176 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010799	A1	20010215	WO 2000-US21257	20000803
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6492553	B1	20021210	US 1999-368213	19990804
	EP 1212269	A1	20020612	EP 2000-955355	20000803
	EP 1212269	B1	20041027		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506420	T2	20030218	JP 2001-515272	20000803
	AT 280744	E	20041115	AT 2000-955355	20000803
	ES 2230143	T3	20050501	ES 2000-955355	20000803
	HK 1046897	A1	20050415	HK 2002-108269	20021115
PRAI	US 1999-368213	A	19990804		
	US 1998-73007P	P	19980129		
	US 1998-98404P	P	19980831		
	US 1998-98708P	P	19980901		
	US 1998-101056P	P	19980918		
	WO 1999-US1923	A2	19990129		
	WO 2000-US21257	W	20000803		
OS	CASREACT 134:178141; MARPAT 134:178141				
GI					



I


AB The title process comprises, e.g., Ugi condensation of N-protected anthranilic acids, amines, aldehydes, and an isocyanide followed by deprotection and cyclization. Thus, 2-(BocMeN)C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, imidazole-1-propanamine, PhCH<sub>2</sub>CH<sub>2</sub>CHO, and an isocyanide were combined to give title compound I.

IT **214854-07-6P 325954-59-4P 325954-60-7P**  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (preparation of oxoazacycloalkanes and analogs)

RN 214854-07-6 CAPLUS




CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 325954-59-4 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetamide, N-butyl-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo- $\alpha$ -(2-phenylethyl)-3-(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)



RN 325954-60-7 CAPLUS


CN 4H-1,4-Benzodiazepine-4-acetamide, 1,2,3,5-tetrahydro-1-methyl-2,5-dioxo- $\alpha$ -phenyl-N,3-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1999:495272 CAPLUS Full-text  
 DN 131:130011  
 TI Preparation of N-acyl-2-aminoacetamides and cyclization products thereof.  
 IN Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere,  
 Richard F.; Mason, Helen J.; Morrisette, Matthew M.; Ma, Liang; Cherrier,  
 Marie-Pierre  
 PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 156 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938844	A1	19990805	WO 1999-US1923	19990129
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318601	AA	19990805	CA 1999-2318601	19990129
	AU 9924821	A1	19990816	AU 1999-24821	19990129
	AU 747987	B2	20020530		
	ZA 9900729	A	20000110	ZA 1999-729	19990129
	EP 1051397	A1	20001115	EP 1999-904421	19990129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9908207	A	20001128	BR 1999-8207	19990129
	JP 2002501944	T2	20020122	JP 2000-530081	19990129
	US 6492553	B1	20021210	US 1999-368213	19990804
	NO 2000003792	A	20000927	NO 2000-3792	20000724
	BG 104724	A	20010330	BG 2000-104724	20000829
PRAI	US 1998-73007P	A2	19980129		
	US 1998-98404P	A2	19980831		
	US 1998-98708P	A2	19980901		
	US 1998-101056P	A2	19980918		
	WO 1999-US1923	W	19990129		
OS	MARPAT 131:130011				
AB	RaRbNCRcaRcbRd .Ra = RaaCO; Dd = CONHRda; Raa, Rb, Rca, Rcb = H, (substituted) alipharyl, aryl; Rda = (substituted) alipharyl, aryl; with provisos were prepared by reaction of RcaCORcb with RbNH2, RaCO2H, and NCRda. Title compds. may be prepared on a isocyanide resin and deprotected/cyclized to give 1,4-benzodiazepine-2,5-diones, diketopiperazines, ketopiperazines, lactams, 1,4-benzodiazapines, and dihydroquinoxalinones.				
IT	214854-07-6P 234781-74-9P 234781-75-0P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of N-acyl-2-aminoacetamides and cyclization products thereof)				
RN	214854-07-6 CAPLUS				
CN	1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)				




RN 234781-74-9 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetamide, N-butyl-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo- $\alpha$ -(2-phenylethyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234781-75-0 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetamide, 1,2,3,5-tetrahydro-1-methyl-2,5-dioxo- $\alpha$ -phenyl-N,3-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1999:197527 CAPLUS Full-text  
 DN 130:325356  
 TI Enantioselective Synthesis of  $\alpha$ -Amino Acids from Chiral  
 1,4-Benzodiazepine-2,5-diones Containing the  $\alpha$ -Phenethyl Group  
 AU Juaristi, Eusebio; Leon-Romo, Jose Luis; Ramirez-Quiros, Yara  
 CS Departamento de Quimica Centro de Investigacion y de Estudios Avanzados,  
 Instituto Politecnico Nacional, Mexico City, 07000, Mex.  
 SO Journal of Organic Chemistry (1999), 64(8), 2914-2918  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 130:325356  
 GI



AB Chiral benzodiazepinedione (S)-I was prepared in good yield from N-methylisatoic anhydride and (S)- $\alpha$ -phenylethylamine. Enolate (S)-I-Li was alkylated in high yield and with good diastereoselectivity with various electrophiles and in the presence of HMPA as cosolvent. Hydrolysis of the main products with 57% HI proceeded in excellent yield to afford enantiopure  $\alpha$ -substituted  $\alpha$ -amino acids.

IT 223755-94-0P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(enantioselective synthesis of  $\alpha$ -amino acids from chiral benzodiazepinediones containing the  $\alpha$ -phenethyl group)

RN 223755-94-0 CAPLUS



CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-4-[(1S)-1-phenylethyl]-3-(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1998:632419 CAPLUS Full-text  
 DN 130:3837  
 TI Improved Procedure for the Solution Phase Preparation of  
 1,4-Benzodiazepine-2,5-dione Libraries via Armstrong's Convertible  
 Isonitrile and the Ugi Reaction  
 AU Hulme, Christopher; Peng, John; Tang, Sheng-Yuh; Burns, Christopher J.;  
 Morize, Isabelle; Labaudiniere, Richard  
 CS Lead Discovery Department, Rhone-Poulenc Rorer Central Research,  
 Collegeville, PA, 19426-0995, USA  
 SO Journal of Organic Chemistry (1998), 63(22), 8021-8023  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI




AB Title compds. I (R1 = (CH3)2CH, CH3(CH2)5, C6H5CH2CH2, CH3CH2, etc.; R2 =  
 C6H5CH2, C6H5CH2CH2, C6H5(CH2)3, 4-MeOC6H4CH2, CH3(CH2)5, etc.; R3 = H, CH3)  
 were prepared from R1CHO, R2NH2, 1-cyclohexenylisonitrile, and II by 4-  
 component condensation in methanol at room temperature  
 IT 214854-07-6P 215650-70-7P 215650-73-0P  
 215650-74-1P 215650-75-2P 215650-86-5P  
 215650-89-8P 215650-90-1P 215650-91-2P  
 215651-02-8P 215651-05-1P 215651-06-2P  
 215651-07-3P 215651-17-5P 215651-20-0P  
 215651-21-1P 215651-22-2P 215651-65-3P  
 215651-66-4P 215651-77-7P 215651-80-2P  
 215651-81-3P 215651-82-4P 215651-93-7P  
 215651-96-0P 215651-97-1P 215651-98-2P  
 215652-07-6P 215652-09-8P 215652-10-1P  
 215652-21-4P 215652-24-7P 215652-25-8P  
 215652-26-9P 215652-37-2P 215652-40-7P  
 215652-41-8P 215652-42-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (procedure for solution phase preparation of benzodiazepinedione libraries  
 via  
 Armstrong's convertible isonitrile and Ugi reaction)  
 RN 214854-07-6 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-  
 yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215650-70-7 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(2-phenylethyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 215650-73-0 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 215650-74-1 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 215650-75-2 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(phenylmethyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)

NAME)




RN 215650-86-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3,4-bis(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215650-89-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215650-90-1 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215650-91-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(2-phenylethyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215651-02-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(2-phenylethyl)-4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 215651-05-1 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 215651-06-2 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)






RN 215651-07-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(3-phenylpropyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215651-17-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[(4-methoxyphenyl)methyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215651-20-0 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-4-[(4-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 215651-21-1 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-4-[(4-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 215651-22-2 CAPLUS  
 CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-4-[(4-methoxyphenyl)methyl]-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215651-65-3 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 215651-66-4 CAPLUS  
 CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215651-77-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-3-(2-phenylethyl)-4H-1,4-benzodiazepin-4-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 215651-80-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-4H-1,4-benzodiazepin-4-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 215651-81-3 CAPLUS


CN Benzenesulfonamide, 4-[2-[3-[(3,3-dimethylcyclohexyl)methyl]-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-4H-1,4-benzodiazepin-4-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 215651-82-4 CAPLUS  
 CN Cyclopropanecarboxylic acid, 2-[4-[2-[4-(aminosulfonyl)phenyl]ethyl]-2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215651-93-7 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215651-96-0 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 215651-97-1 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 215651-98-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[4-[[4-(1,1-dimethylethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215652-07-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(2-phenylethyl)-4-(5-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 215652-09-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(5-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 215652-10-1 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(5-quinolinylmethyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215652-21-4 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 4-(2,2-diphenylethyl)-3,4-dihydro-1-

methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215652-24-7 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-4-(2,2-diphenylethyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 215652-25-8 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-4-(2,2-diphenylethyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 215652-26-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[4-(2,2-diphenylethyl)-2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215652-37-2 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-4-[3-(2-oxo-1-pyrrolidinyl)propyl]-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 215652-40-7 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 215652-41-8 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 215652-42-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-[3-(2-oxo-1-pyrrolidinyl)propyl]-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)






IT 215651-64-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (solution phase preparation of benzodiazepinediones via Armstrong's  
 convertible  
 isonitrile and Ugi reaction)


RN 215651-64-2 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[1-(1,3-benzodioxol-5-yl)ethyl]-3,4-  
 dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1998:624893 CAPLUS Full-text  
 DN 129:316200  
 TI Novel safety-catch linker and its application with a Ugi/De-  
 BOC/cyclization (UDC) strategy to access carboxylic acids,  
 1,4-benzodiazepines, diketopiperazines, ketopiperazines and  
 dihydroquinoxalinones  
 AU Hulme, Christopher; Peng, John; Morton, George; Salvino, Joseph M.;  
 Herpin, Tim; Labaudiniere, Richard  
 CS Rhone-Poulenc Rorer Cent. Res., Collegeville, PA, 19426, USA  
 SO Tetrahedron Letters (1998), 39(40), 7227-7230  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 GI



AB This communication reveals the synthesis and application of a novel resin bound isonitrile (I; Al = isocyano; P = Wang resin) which can be used for automated parallel synthesis of diverse arrays of compds. in combinatorial chemical. The resin is an example of a novel safety-catch linker which upon BOC-activation can be resin cleaved with a variety of nucleophiles. Use of this polymer supported isonitrile in the Ugi multi-component reaction (MCR) with aldehydes R1CHO (R1 = unspecified aldehyde residue), amines R2NH2 (R2 = unspecified amine residue), and carboxylic acids R3CO2H (R3 = unspecified carboxylic acid residue) to form resin-bound Ugi products I (Al = Q, R = H) followed by Boc-activation to I (Al = Q, R = Boc) (i.e. safety catch) and resin clipping and cyclization. allows access to diverse arrays of 1,4-benzodiazepine-2,5-diones (II; R4 = unspecified substituent), diketopiperazines (III), ketopiperazines (IV), and dihydroquinoxalines (V), resp., as well as carboxylic acids (amino acids) (HO-Q) or their esters. The methoxide safety-catch clipping strategy and subsequent solution phase cyclization. offers similar advantages to a traceless linker.


IT 214854-07-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (safety-catch linker resin and its application with  
 Ugi/De-BOC/cyclization strategy to access carboxylic acids,  
 benzodiazepines, diketopiperazines, ketopiperazines and

dihydroquinoxalinones)


RN 214854-07-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 23      THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1996:705648 CAPLUS Full-text  
 DN 126:31333  
 TI A Remarkable Two-Step Synthesis of Diverse 1,4-Benzodiazepine-2,5-diones  
 Using the Ugi Four-Component Condensation  
 AU Keating, Thomas A.; Armstrong, Robert W.  
 CS Department of Chemistry and Biochemistry, University of California, Los  
 Angeles, CA, 90095, USA  
 SO Journal of Organic Chemistry (1996), 61(25), 8935-8939  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI




AB A two-step, general synthesis of 1,4-benzodiazepine-2,5-diones was presented. This synthesis employed an Ugi four-component condensation using a convertible isocyanide (1-isocyanocyclohexene), followed by an acid-activated cyclization reaction. The condensation of 2-amino-5-iodobenzoic acid with 1-butanamine, benzaldehyde and 1-isocyanocyclohexene gave 4-butyl-3,4-dihydro-7-iodo-3-phenyl-1H-1,4-benzodiazepine-2,5-dione (I). This synthesis represented a dramatically improved route to 1,4-benzodiazepine-2,5-diones over those currently in the literature. In addition, since amino acids are not used as inputs, the potential for mol. diversity is much greater than that with existing syntheses. It was also found that 1,4-benzodiazepine-2,5-diones substituted with methylenes at the C-3 and N-4 positions display conformational isomerism in the NMR spectra at room temperature. Variable-temperature NMR expts. support this observation and offer the interesting conclusion that the 1,4-benzodiazepine-2,5-dione core structure, in certain examples, might not be as rigid as previously supposed.

IT 184287-14-7P 184287-20-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of benzodiazepinediones by Ugi four-component condensation)


RN 184287-14-7 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(4-methylphenyl)-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 184287-20-5 CAPLUS


CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-3-(4-methylphenyl)-1-phenyl-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



=> d l2; d his; log y

L2 HAS NO ANSWERS

L1 STR



G1 Cb,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 12:20:46 ON 30 NOV 2005)

FILE 'REGISTRY' ENTERED AT 12:20:52 ON 30 NOV 2005

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 7 S L2

L4 174 S L2 FUL

FILE 'CAPLUS' ENTERED AT 12:21:18 ON 30 NOV 2005

L5 13 S L4

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

65.12

226.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

-9.49

-9.49

STN INTERNATIONAL LOGOFF AT 12:22:27 ON 30 NOV 2005